Immune Thrombocytopenia (ITP): Current Limitations in Patient Management

Area of Science:

• Hematology
• Immunology
• Autoimmune Diseases

Background:

• Primary immune thrombocytopenia (ITP) is an autoimmune disorder causing low platelet counts due to increased destruction and reduced production.
• Current treatments include corticosteroids, IVIg, anti-D Ig, splenectomy, rituximab, and TPO-RAs, with varying efficacy and side effects.
• Despite advances, significant unmet needs exist in ITP management, particularly concerning patient-reported outcomes (PROs).

Purpose of the Study:

• To review the management of newly diagnosed and refractory ITP patients.
• To critically evaluate current ITP therapies, focusing on their limitations from a patient's perspective.
• To emphasize the importance of PROs and the need for individualized treatment strategies.

Main Methods:

• This is a narrative review discussing existing literature on ITP management.
• Focus is placed on analyzing the impact of therapies on patient-reported outcomes and quality of life.
• The review synthesizes information on limitations of current treatments and suggests future research directions.

Main Results:

• First-line corticosteroids do not demonstrably improve health-related quality of life in ITP patients and may cause adverse effects.
• Long-term corticosteroid use can negatively impact quality of life through sleep disturbance, weight gain, and mental health issues.
• Many therapies for refractory ITP offer transient benefits, necessitating better approaches for sustained symptom control and reduced toxicity.

Conclusions:

• Current ITP therapies have limitations, especially regarding their impact on patient well-being and quality of life.
• There is a critical need for individualized treatment strategies that consider treatment response, symptom burden, and adverse effects.
• Implementing validated screening tools for PROs is essential for comprehensive ITP patient care beyond laboratory values.